COMPLIMENT CORP

Compliment Corporation is a start-up biotechnology company with a new approach to checkpoint inhibition in oncology, a multi-billion-dollar market opportunity. Our proprietary technology platform is based on a novel engineered protein that increase the efficacy of widely used cancer therapies, such as monoclonal antibodies. Our lead product disables the complement-inhibitory protein CD46, which reduces the anti-tumor effects of monoclonal antibodies. This protein, Ad35K++, is an immune checkpoint technology targeting the complement system. It enhances the anti-tumor therapeutic effects of several monoclonal antibodies, including Rituxan and Herceptin, in both hematologic malignancies and solid tumors. A study published in the Nature journal, Molecular Therapy, demonstrated in non-human primates that the combination of Rituxan and Ad35K++ was able to eliminate B cells, while treatment with the same dose of Rituxan alone had no effect. These primate studies also confirmed previous safety..

Also known as: Compliment Corporation

Primary location: Seattle United States